Cancer Diet Shared by Healthy Cells

Tumor cells rapidly divide by usurping a metabolic trick from normal cell development.

Written byBeth Marie Mole
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

WIKIMEDIA, REYTANTo fuel runaway tumor growth, cancer cells use a metabolic mechanism, called glycolysis, that normal cells were believed to only use in the absence of oxygen. But according to a study released today (January 23) in Cancer & Metabolism, certain progenitor cells use glycolysis to power rapid growth during early tissue development, even when oxygen is readily available—suggesting that tumors arise out of the normal metabolic processes for tissue growth.

“They demonstrate nicely that [aerobic glycolysis] is required in normal development,” said cancer genetics researcher Chi Van Dang, director of University of Pennsylvania’s Abramson Cancer Center, who was not involved in the study. Moreover, he adds, the study highlights the importance of tightly regulated metabolism and cell growth—whether to spur early tissue development or unbridled tumor development. Before this study, “the prevailing viewpoint was that metabolism was just along for the ride.” (Read an in-depth discussion of the role of metabolism in complex diseases in The Scientist’s 2011 feature, “Power Failure.”)

Unlike the controlled diet of normal cells that make energy from pyruvate in the presence of oxygen, cancer cells gobble up glucose and convert it to lactic acid. Why and how tumors utilize this ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies